Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 4, 2003, Pages 791-797

  Aubert, H ^a   Frere C ^a   Aillaud, M F ^a   Morange, P E ^a   Juhan Vague, I ^a   Alessi, M C ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

Adipose tissue; Insulin resistance syndrome; Obesity; Thrombin activatable fibrinolysis inhibitor (TAFI)

Indexed keywords

BIOLOGICAL MARKER; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADIPOSE TISSUE; ADULT; ARTICLE; BLOOD; FEMALE; HUMAN; INSULIN RESISTANCE; MIDDLE AGED; OBESITY; PATHOLOGY; TISSUE DISTRIBUTION; VASCULAR ENDOTHELIUM;

ADIPOSE TISSUE; ADULT; BIOLOGICAL MARKERS; CARBOXYPEPTIDASE U; ENDOTHELIUM, VASCULAR; FEMALE; FIBRINOGEN; HUMANS; INSULIN RESISTANCE; MIDDLE AGED; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE DISTRIBUTION;

EID: 0142137406     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00147.x     Document Type: Article

References (24)

1. Hendriks D, Scharpe S, van Sande M, Lommaert MP Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N. J Clin Chem Clin Biochem 1989; 27: 277-85.
2. Hendriks D, Wang W, Scharpe S, Lommaert MP, van Sande M. Purification and characterization of a new arginine carboxypeptidase in human serum. Biochim Biophys Acta 1990; 1034: 86-92.
3. Redlitz A, Tan AK, Eaton DL, Plow EE Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995; 96: 2534-8.
4. Bajzar L, Kalafatis M, Simioni P, Tracy PB. An antifibrinolytic mechan ism describing the prothrombotic effect associated with factor V Leiden. J Biol Chem 1996; 271: 22949-52.
5. Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifi brinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997; 2: 14477-82.
6. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-81.
7. SilveiraA, SchattemanK, GoossensF, Moor E, Scharpe S, StromqvistM, Hendriks D, Hamsten A. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 2000; 84: 364-8.
8. van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000: 2855-9.
9. Hori Y, Gabazza EC, Yano Y, Katsuki A, Suzuki K, Adachi Y, Sumida Y Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 660-5.
10. Juhan-Vague I, Renucci JF, Grimaux M, Morange PE, Gouvernet J, Gourmelin Y, Alessi MC. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler Thromb Vase Biol 2000; 20: 2156-61.
11. Eaton DL, Malloy BE, Tsai SP, Henzel W, Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypep tidase B from human plasma. J Biol Chem 1991; 266: 21833-8.
12. Van Thiel DH, George M, Fareed J. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease. Thromb Haemost 2001; 85: 667-70.
13. Marx PF, Wagenaar GT, Reijerkerk A, Tiekstra MJ, van Rossum AG, Gebbink MF, Meijers JC. Characterization of mouse thrombin-activa table fibrinolysis inhibitor. Thromb Haemost 2000; 83: 297-303.
14. Bouma BN, Marx PF, Mosnier LO, Meijers JC. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarbox ypeptidase R, procarboxypeptidase U). Thromb Res 2001; 101: 329-54.
15. Gils A, Brouwers E, Peeters M, Marx P, Alessi MC, Bouma BN, Juhan-Vague I, Declerck PJ. Development of a genotype 325 specific proCPU/TAFI ELISA. Congress of the International Society of Fibrinolysis and Proteolysis, Munich, Germany, 8-11 September 2002: Abstract 73.
16. Latron Y, Chautan M, Anfosso F, Alessi MC, Nalbone G, Lafont H, Juhan-Vague I. Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler Thromb 1991; 11: 1821-9.
17. Alessi MC, Bastelica D, Morange P, Berthet B, Leduc I, Verdier M, Geel O, Juhan-Vague I. Plasminogen activator inhibitor 1, transforming growth factor-betal, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 2000; 49: 1374-80.
18. Bastelica D, Morange P, Berthet B, Borghi H, Lacroix O, Grino M, Juhan-Vague I, Alessi MC. Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differ ences between visceral and subcutaneous deposits. Arterioscler Thromb Vase Biol 2002; 22: 173-8.
19. Juhan-Vague I, Morange PE, Aubert H, Henry M, Aillaud MF, Alessi MC, Samnegard A, Hawe E, Yudkin J, Margaglione M, Di Minno G, Hamsten A, Humphries SE. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vase Biol 2002; 22: 867-73.
20. Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracy RP. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2000; 152: 897-907.
21. Sato T, Miwa T, Akatsu H, Matsukawa N, Obata K, Okada N, Campbell W, Okada H. Pro-carboxypeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase N is not. J Immunol 2000; 165: 1053-8.
22. Campbell W, Okada N, Okada H. Carboxypeptidase R is an inactivator of complement-derived inflammatory peptides and an inhibitor of fibrinolysis. Immunol Rev 2001; 180: 162-7.
23. Boffa MB, Hamill JD, Bastajian N, Dillon R, Nesheim ME, Koschinsky ML. A role for CCAAT/enhancer binding protein (C/EBP) in hepatic expression of thrombin activable fibrinolysis inhibitor (TAFI). J Biol Chem 2002; 8: 8.
24. Poli V The role of C/EBP isoforms in the control of inflammatory and native immunity functions. J Biol Chem 1998; 273: 29279-82.